Loading…
Decoy Therapeutics Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in DCOY.
▼ -100.0% over 5Y.
today you would have $0.08▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 11 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $7.79 | $331.20 | $936.00 | $2,203.20 | $17,856.00 | $32,760.00 | $136,080.00 | $297,000.00 | $3,141,000.00 | $4,752,000.00 | $11,205,000.00 | |
| P/S | 13.8x | — | — | — | — | 12.6x | 7.8x | 14.9x | 3.0x | 49.3x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MNDRMobile-health Network Solutions | $1.55 | — | 0.1x | — | -47.59% | $1.85M |
| EDVAEndovia Health Sciences, Inc. | $0.31 | — | — | — | — | $1.99M |
| SLXNSilexion Therapeutics Corp | $0.36 | — | 0.4x | — | — | $2.02M |
| AEMDAethlon Medical Inc | $2.49 |
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
Company description provided by Yahoo Finance.
| 94.0x |
| — |
| P/B | 1.6x | 0.7x | 2.1x | 0.6x | 0.4x | 0.6x | 1.8x | 4.9x | — | — | 1.6x | 2.4x |
| EPS | -$129.10 | -$69.54 | -$5,533.20 | -$21,427.20 | -$11,116.80 | -$18,000.00 | -$76,320.00 | -$41,760.00 | -$1,791,000.00 | -$2,187,000.00 | -$1,872,000.00 |
| Profit margin | -447.01% | — | — | — | — | -693.84% | -140.49% | -200.18% | -85.56% | -2701.74% | -3907.65% | — |
| ROE | -66.58% | -212.58% | -368.84% | -237.22% | -304.37% | -32.97% | -33.18% | -65.55% | — | — | -66.58% | -31.61% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.2x |
| — |
| -160.91% |
| $1.77M |
| IMCCIM Cannabis Corp. | $3.41 | — | — | — | — | $2.06M |
| SHPHShuttle Pharmaceuticals Holdings, Inc. | $3.54 | 39.3x | 0.6x | — | -326.36% | $2.07M |